An atypical sarcoid-like reaction during anti-protein death 1 treatment in a patient with metastatic melanoma
- 21 July 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 30 (5) , 524-527
Abstract
We report a case of anti-protein death 1-induced sarcoid-like reaction in a 63-year-old Caucasian male who was diagnosed with stage IV-M1a melanoma. He was initially treated with pembrolizumab monotherapy (Q3W) and had a complete response after 14 cycles. However, relapse was suspected 3 months later with appearance of hilar, mediastinal and hepatic hilar lymph nodes as well as a skin lesion. Biopsy of both the hilar lymph nodes and the skin lesion demonstrated sarcomatoid granulomatosis. Pembrolizumab was discontinued temporarily. While on 18F-FDG-PET/CT, all sarcoid-like lesions regressed in size and activity, a new hypermetabolic solitary skeletal lesion was detected in a lumbar vertebra, suspicious for metastasis. However, since the patient was asymptomatic, a watchful-waiting attitude was taken. During this period, a spontaneous and complete resolution of the metabolic activity was observed of the skeletal lesion. Until today, the patient remains in complete remission. Current case presents an atypical presentation and evolution of anti-PD-1-induced sarcoid-like reaction, illustrating the difficulty of differentiating it from disease progression. Before considering (re-)initiation of anti-melanoma therapy, a tissue biopsy of one of the suspected lesions may be performed to confirm diagnosis. Physicians treating patients with ICI should be aware of this difficulty and critically assess the nature of lesions suspect of progression in patients responding to ICI and presenting with a sarcoid-like reaction.Keywords
This publication has 19 references indexed in Scilit:
- SarcoidosisNature Reviews Disease Primers, 2019
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillanceNature Reviews Clinical Oncology, 2019
- 18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumabMelanoma Research, 2019
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trialThe Lancet Oncology, 2018
- Sarcoidosis-Like Reactions Induced by Checkpoint InhibitorsJournal of Thoracic Oncology, 2018
- Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastasesThe Lancet Oncology, 2018
- Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1European Journal of Cancer, 2018
- Sarcoid-like reactions in patients receiving modern melanoma treatmentMelanoma Research, 2018
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III MelanomaNew England Journal of Medicine, 2018
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV MelanomaNew England Journal of Medicine, 2017